2024 Update: How Health Plan Leaders Are Handling the GLP-1 Cost Crisis
Health Plan Executives Weigh In on GLP-1 Cost Crisis
To understand how the GLP-1 cost crisis is evolving and how health plan leaders are approaching it, Virta surveyed 60 Chief Medical Officers, Chief Pharmacy Officers and actuarial leaders in late 2023. Read this report to learn more about the exponential growth of weight loss drugs and how executives are mitigating the risk, including:
- Why GLP-1 growth outpaced expectations in 2023 and why half of execs predict it will be a top 3 drug class in 2024
- How lifestyle programs have factored in to GLP-1 strategies and why investment is on the rise
- What is working to protect organizations from surging GLP-1 costs
This survey follows up with executives who participated in Virta's March 2023 research on GLP-1s, offering a unique perspective on the change happening in this highly dynamic space.
2024 Update: How Health Plan Leaders Are Handling the GLP-1 Cost Crisis
Health Plan Executives Weigh In on GLP-1 Cost Crisis
To understand how the GLP-1 cost crisis is evolving and how health plan leaders are approaching it, Virta surveyed 60 Chief Medical Officers, Chief Pharmacy Officers and actuarial leaders in late 2023. Read this report to learn more about the exponential growth of weight loss drugs and how executives are mitigating the risk, including:
- Why GLP-1 growth outpaced expectations in 2023 and why half of execs predict it will be a top 3 drug class in 2024
- How lifestyle programs have factored in to GLP-1 strategies and why investment is on the rise
- What is working to protect organizations from surging GLP-1 costs
This survey follows up with executives who participated in Virta's March 2023 research on GLP-1s, offering a unique perspective on the change happening in this highly dynamic space.